Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management

BACKGROUND: The anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies have shown exceptional activity in many cancers. However, these immunotherapies can also result in diverse adverse cutaneous eruptions that need to be better characterized for ongoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, John, Chang, Jason, Mendenhall, Melody, Cherry, Grace, Goldman, Jonathan W., Kulkarni, Rajan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784551/
https://www.ncbi.nlm.nih.gov/pubmed/29383039
http://dx.doi.org/10.1177/1758834017751634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784551/
https://www.ncbi.nlm.nih.gov/pubmed/29383039
http://dx.doi.org/10.1177/1758834017751634

Ejemplares similares